TLX News: Targeted Alpha Therapy Candidate: Bladder Cancer Study Completes Enrolment - 24th Aug 2022, 7:56am

[annb0t]

MELBOURNE, Australia and NANTES, France, Aug. 24, 2022 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and Nantes-based ATONCO S.A.S. ('ATONCO') today announced that the final patient has been dosed in a Phase I study of TLX250-CDx in patients with non-muscle invasive bladder cancer (NMIBC) at the Institut de Cancérologie de l'Ouest (ICO) in St Herblain, France. (PRNewsfoto/Telix Pharmaceuticals Limited)

The objective of 'PERTINENCE' (NCT04897763), an in...

>>> Read more: Targeted Alpha Therapy Candidate: Bladder Cancer Study Completes Enrolment